Welcome to Markets Desk, here's what's moving the needle right now.
The labor market is flashing a warning sign. ADP's August private payrolls print came in at just thirty-eight thousand new jobs, the weakest reading in seven months and the second consecutive soft figure. That points to a genuine summer hiring slowdown that could shift the conversation at the Fed considerably.
Pivoting to corporate news, Uber announced it is cutting roughly ten percent of its workforce, framing the move as a push to run leaner and faster. Small internal teams are being cut by nearly half, and remote work is being pulled back sharply, with only about one percent of staff allowed to continue working offsite. Cost discipline is clearly back in fashion.
And in pharma, Teva is catching a bid after reporting positive Phase two-a results for TEV-four-oh-eight, its investigational anti-IL-fifteen antibody targeting celiac disease. Early-stage data rarely moves the needle definitively, but a clean topline read in an underserved indication gives Teva's pipeline a credible new thread worth watching as the trial continues to enroll.
That's the tape. Markets Desk, signing off the floor.
